"We're hoping to foster deeper and more inclusive representations and ally-ship at the intersection of art and technology." VlatkoRadovic/Getty Images

As Pride Month winds down, a new nonprofit is ramping up efforts to provide resources, training, financial aid, and networking opportunities for LGBTQ+ members of Houston's tech and creative communities.

Co-founders Alan Lett, creative director at event management company Staging Solutions, and Anthony Ferrell, a Microsoft store manager, officially launched Luminiris on June 25. Luminiris states that it's "committed to illuminating a new generation of the creative class seeking to pursue careers in the creative or tech fields — and give back along the way."

"Houston is a city overwhelmed with talent, both artistic and technical. We've also got a strong and diverse LGBTQ+ community," Lett says in a Luminiris video on YouTube.

The name of the organization is a mashup of the Latin word "lumen," meaning light, and the Greek word "iris," meaning color.

"We want Luminiris to be a resource for the community, connecting creative types with technical minds in a professional setting. We're hoping to foster deeper and more inclusive representations and ally-ship at the intersection of art and technology. Through Luminiris, we want to promote LGBTQ+ talent in these fields," Lett and Ferrell say in a June 24 release.

Luminiris is assuming responsibility for the Microsoft Pride Mixer hosted by Staging Solutions. Lett and Farrell started the mixer five years ago. The Pride Mixer will be the organization's flagship event, held every year on the Friday night before the Houston Pride Festival at the George R. Brown Convention Center.

Since the 2020 Pride festival and parade are postponed, the mixer isn't being held this year. But Luminiris plans to bring it back in 2021.

Throughout the rest of this year, Luminiris will focus on monthly virtual social events and online workshops for tech and creative professionals. It also will be collaborating with local networks for tech and creative professionals to help LGBTQ+ nonprofits and causes with graphic design, visual media, software training, and tech know-how.

"Too many times, smaller nonprofits are blocked by the shadows of larger, developed nonprofits. … I can't wait to see the impact Luminiris will have on those who were once in the shadows," Atlantis Narcisse, founder of Save Our Sisters United, says in the Luminiris release.

Save Our Sisters is a Houston-based advocacy group that serves cisgender and transgender women of color. Narcisse was one of the honorary grand marshals of last year's Pride parade in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”